Initial voriconazole trough blood levels and clinical outcomes of invasive aspergillosis in patients with hematologic malignancies

Evidence-Based Guidelines for Empirical Therapy of Neutropenic Fever in Korea

(2011) Dong-Gun Lee et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

Serial Plasma Voriconazole Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation

(2009) S. M. Trifilio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype

(2009) Ina Scholz et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Voriconazole concentrations and outcome of invasive fungal infections

(2009) S. Miyakis et al.   CLINICAL MICROBIOLOGY AND INFECTION

Voriconazole therapeutic drug monitoring: focus on safety

(2009) Alessandro C Pasqualotto et al.   Expert Opinion On Drug Safety

Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders

(2009) Koki Ueda et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

(2008) Brahm H. Segal et al.   CLINICAL INFECTIOUS DISEASES

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

(2008) Ben De Pauw et al.   CLINICAL INFECTIOUS DISEASES

Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes

(2007) A. Pascual et al.   CLINICAL INFECTIOUS DISEASES